Efficacy, safety and pharmacokinetics of a new high-purity factor X concentrate in subjects with hereditary factor X deficiency.

Austin, S K; Kavakli, K; Norton, M; Peyvandi, F; Shapiro, A

Austin, S K; Kavakli, K; Norton, M; Peyvandi, F; Shapiro, A.

Affiliation

Austin SK; St. George's Haemophilia Centre, St. George's University Hospitals NHS Foundation Trust, London, UK.
Kavakli K; Department of Pediatric Hematology, Children's Hospital, Ege University Faculty of Medicine, Izmir, Turkey.
Norton M; Bio Products Laboratory, Elstree, UK.
Peyvandi F; Angelo Bianchi Bonomi Hemophilia & Thrombosis Center, Milan, Italy.
Shapiro A; Department of Pathophysiology and Transplantation, Università degli Studi di Milano, Milan, Italy.

Haemophilia ; 22(3): 419-25, 2016 May.

Article in En | MEDLINE | ID: mdl-27197801

Subject(s)

Factor X Deficiency/drug therapy; Factor X/therapeutic use; Adolescent; Adult; Antibodies, Neutralizing/blood; Blood Coagulation Tests; Child; Factor X/adverse effects; Factor X/pharmacokinetics; Factor X Deficiency/congenital; Factor X Deficiency/pathology; Female; Half-Life; Hemorrhage/prevention & control; Humans; Male; Menorrhagia/prevention & control; Middle Aged; Severity of Illness Index; Treatment Outcome; Young Adult

Key words

clinical trial; clotting factor concentrate; efficacy; factor X deficiency; orphan drug; safety

Fulltext

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Health context: 1_ASSA2030 Database: MEDLINE Main subject: Factor X / Factor X Deficiency Type of study: Clinical_trials Limits: Adolescent / Adult / Child / Female / Humans / Male / Middle aged Language: En Journal: Haemophilia Year: 2016 Document type: Article

Fulltext

XML

PubMed Links

Search on Google